Adagene (ADAG) announced data at the SITC 39th Annual Meeting, taking place in Houston, Nov. 6 – 10, 2024. The two poster presentations ...

Xilio is leveraging its proprietary platform to advance a pipeline of research-stage programs for tumor-activated bispecific ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regu ...

Methods: Forty-nine OSCC patients were enrolled. One TDLN per patient was analysed using flow cytometry to profile immune-checkpoint expression (PD-1, CTLA-4, TIGIT, TIM-3, LAG-3) and other markers ...

Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the presentation of new data on two of its promising investigational ...

CXCR3KO mice displayed a markedly reduced response to anti-PD-1 and anti-CTLA-4 therapy. Results from a panel of in vivo and ex vivo 3D tumor models imply that, beyond driving CD8+ T cells into T-cell ...

A large population of key cells with major immunosuppressive effects are involved in immune evasion in HCC, including regulatory T (Treg) cells, myeloid-derived suppressor cells (MDSCs ... PD-1/PD-L1 ...

As I understand it, COYA 301 promotes Treg function, and CTLA-4 Ig keeps Tregs from senescence and apoptosis, enhancing the therapeutic window. These are the results seen with LD IL-2 + CTLA-4 Ig ...

Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of potentially best-in-class IL-2 therapeutics, today shared positive results from its Phase 1/2 ...